AbbVie v. Annora Pharma Private Limited (1:26-cv-00688): litigation status, claims at issue, and Paragraph IV/ANDA risk mapping What is AbbVie […]

Vertex Pharmaceuticals v. MSN Pharmaceuticals (1:26-cv-00306): Litigation Summary, Claims at Issue, and Near-Term Patent/ANDA Exposure Vertex Pharmaceuticals Incorporated sued MSN

Litigation Summary and Analysis: Novartis Pharmaceuticals Corporation v. Cipla USA Inc. (D.N.J.) | Case No. 1:26-cv-00272 Executive summary. The action

Litigation summary and analysis: Boehringer Ingelheim Pharmaceuticals Inc. v. Ridhisidhi PLLC, 1:26-cv-00372 Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) sued Ridhisidhi PLLC

Ultragenyx Pharma v. Navinta 2:26-cv-03585: Litigation Summary, Claims, and Business Impact Executive summary: The case Ultragenyx Pharmaceutical Inc. v. Navinta

SHIONOGI v. LUPIN (2:26-cv-06218): Litigation Summary, Patent Estate Impact, and Generic Launch Risk Shionogi Inc. v. Lupin Limited, case number

A patent expiry for a blockbuster drug is not a legal event. It’s a commercial trigger. The twelve months before

The biosimilar wave was supposed to be simple. Blockbuster biologics lose patent protection, cheaper copies enter the market, prices collapse,

The assumption is logical: if a tool costs nothing, you save money using it. That arithmetic breaks down badly when